Bicara Therapeutics IncNASDAQ:BCAX
- LAST PRICE25.6000
- TODAY'S CHANGE (%)-0.1500 (-0.5825%)
- Bid / Lots25.5500/ 1
- Ask / Lots25.9000/ 4
- Open / Previous Close25.8900 / 25.7500
- Day Range
- 52 Week Range
- Volume6,463
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCAX |
|---|---|---|
| 09:32 ET | 342 | 25.5 |
| 09:34 ET | 300 | 25.39 |
| 09:43 ET | 3800 | 25.48 |
| 09:48 ET | 100 | 25.45 |
| 09:57 ET | 100 | 25.35 |
| 10:06 ET | 100 | 25.5 |
| 10:12 ET | 100 | 25.6 |
Sep 16, 2024
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 4:01PM ET on Monday Sep 16, 2024 by Dow Jones
4:01PM ET on Monday Sep 16, 2024 by Dow Jones*DJ Bicara Therapeutics IPO of 20.1M Shares Closed at Price of $18/Shr >BCAX, from 4:01PM ET on Monday Sep 16, 2024 by Dow Jones
4:01PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 13, 2024
DJ Bicara Therapeutics Rises 39% in Debut on Nasdaq, from 2:35PM ET on Friday Sep 13, 2024 by Dow Jones
2:35PM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bicara Therapeutics Inc | 1.3B | -20.4x | --- |
Day One Biopharmaceuticals Inc | 1.3B | -7.5x | --- |
Longboard Pharmaceuticals Inc | 1.3B | -15.7x | --- |
Tyra Biosciences Inc | 1.2B | -14.0x | --- |
Cogent Biosciences Inc | 1.2B | -4.4x | --- |
ARS Pharmaceuticals Inc | 1.3B | -29.8x | --- |
Company Information
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Contact Information
- Headquarters
- 116 Huntington Avenue, Suite 703BOSTON, MA, United States 02116
- Phone
- 617-468-4219
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Michael Powell
- President, Chief Operating Officer
- Ryan Cohlhepp
- Chief Executive Officer, Director
- Claire Mazumdar
- Chief Financial Officer
- Ivan Hyep
- Chief Medical Officer
- David Raben
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.25 |
Book Value | $4.22 |
P/E Ratio | -20.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
